Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06267313 · ClinicalTrials.gov registry record · NA
Attention Training for COVID-19 Related Distress
A NA study, sponsored by Palo Alto University.
- Terminated
- Registry status
- NA
- Development phase
- 6
- Enrollment target
NCT06267313: Clinical Trial NA study, sponsored by Palo Alto University.
NCT06267313 is a NA study that was terminated before completion, run by Palo Alto University. The registered enrollment target is 6 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06267313, a NA study, was terminated before completion, sponsored by Palo Alto University.
- TERMINATED
- Registry status
- NA
- Development phase
- 6 participants
- Enrollment target
Study Summary
The study aims to test whether attention training (attention bias modification or attention control training) reduces distress or COVID-19 related anxiety compared to a neutral condition.
Primary Outcome
The measure is scored using a 5-point time anchored scale (0 = Not at all to 4 = Nearly every day over the last 2 weeks) and scores range between 0 and 20, with higher scores reflecting worse outcome.
Interventions
- BEHAVIORAL Attention Bias Modification
- BEHAVIORAL Attention Control Training
- BEHAVIORAL Neutral training
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2024-02-19 |
| Est. Completion | 2024-11-09 |
| Phase | NA |
Why NCT06267313 stopped before completion
NCT06267313 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 3 interventions - of which Attention Bias Modification is the first listed.
NCT06267313 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06267313 about?
NCT06267313 is a clinical study titled "Attention Training for COVID-19 Related Distress". The study aims to test whether attention training (attention bias modification or attention control training) reduces distress or COVID-19 related anxiety compared to a neutral condition.
What is the current status of trial NCT06267313?
This trial is currently terminated. It is a NA study. The enrollment target is 6 participants. The study started on 2024-02-19. Estimated completion is 2024-11-09.
What interventions are being tested in trial NCT06267313?
The interventions under investigation include: Attention Bias Modification (BEHAVIORAL), Attention Control Training (BEHAVIORAL), Neutral training (BEHAVIORAL).
Who is sponsoring clinical trial NCT06267313?
This trial is sponsored by Palo Alto University, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06267313's enrollment target sits among peer trials
6 1983rd of 2000 higher than 13 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI